跳至主要内容
临床试验/NCT01113151
NCT01113151已完成不适用

Daily Magnesium-supplement With Mablet for Steroid-resistant, Severe Asthmatics

University of Aarhus1 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2011年4月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
5
试验地点
1
主要终点
Asthma control test (ACT)

研究概览

简要总结

The present study is part of a project titled 'Magnesium in asthma and chronic obstructive pulmonary disease'. The hypothesis of the main project is that a daily magnesium supplement will benefit patients with asthma and chronic obstructive pulmonary disease.

The aim of this part of the project is to reveal possible beneficial effects of daily magnesium supplement for severe asthmatics, refractory to conventional treatment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •severe asthmatics, refractory to conventional treatment, including systemic steroid treatment; symptoms must be annual.

排除标准

  • •Se-Mg > 2,00 mmol/L,
  • •smoking cessation less than 1 year prior to study start,
  • •major changes in eating habits within three months prior to study start and during the study period of approximately one year,
  • •various conditions (e.g. gastrointestinal disease, kidney disease, pregnancy/lactation) that may affect the study results.

研究组 & 干预措施

Washout

No Intervention

Mablet

Active Comparator

干预措施: Mablet (Magnesium-supplement) (Dietary Supplement)

Placebo

Placebo Comparator

干预措施: Placebo (Other)

结局指标

主要结局

Asthma control test (ACT)

时间窗: Two years

Questionnaire providing a level of disease control

次要结局

  • EQ-5D(Two years)
  • Spirometry(Two years)
  • Reversibility testing(Two years)
  • Diary(Two years)
  • Adverse effects(Two years)
  • Blood- and urine samples(Two years)
  • Endogen NO in expiratory breath and Impulse Oscillometry.(Two years)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验